ABOUT THIS PODCAST 🔗

Average audio length:
8 minutes
English
United States
48 episodes
since Aug. 11, 2017
episodic

LATEST EPISODE 🔗

Dr Xose Puente speaks with ecancertv at AACR2016 about his discoveries of mutations in non-coding regions driving tumourigensis in chronic lymphocytic leukaemia. Using a library of genomic data from CLL patients, Dr Puente's lab were able to determine point mutations outside of the coding regions …

SEARCH PAST EPISODES

Search past episodes of AACR 2016.

PREVIOUS EPISODES

Dr Martine Piccart presents at AACR 2016 about the results of the MINDACT trial. Using a new diagnostic assay, Mammaprint, to scan for a 70 gene signature, Dr Piccart reports significant predictive potential for determining breast cancer relapse risk.
Dr Robert Gillies talks to ecancertv at AACR 2016 about novel imaging techniques in tumour habitats. Considering the stalling durable response rate of many targeted-therapy patients due to tumour evolution, Dr Gillies discusses the value of multiple imaging techniques to determining tumour habitat…
Dr Xuehong Zhang presents his research at AACR 2016 on risk prediction models, of critical importance to patients evaluating their treatment options, and how to improve the prognostic accuracy of existing models based on novel biomarkers. Dr Zhangs' modified models proved informative to patients a…
Dr Lindsay Morton presents results at AACR 2016 on the risk childhood cancer patients face of developing breast cancer later in life. With a growing population of long-lived cancer survivors, Dr Morton has led investigations into the susceptibility of patients to secondary malignancies in the year…
Dr Philip Low speaks with ecancertv at AACR 2016 about a novel technique to selectively identify tumour cells in vivo. With potentially toxic side effects to uncontrolled tumour lysis and hard-to-target heterogeneity, Dr Low describes a new method of using fluorescein dye to bridge tumours and T C…
Dr Rafaella Sordella speaks with ecancertv at AACR 2016 about cell plasticity affecting its susceptibility to therapies. With specific regard to non-genetic mechanisms of resistance in cancer cells, Dr Sordella explains the flexible cell state, how some cells persist and respond to therapies, and …
Dr Angela deMichele presents results at AACR 2016 from the ISPY2 trial, a novel trial design architecture to determine new drug therapies for patients with Her2 breast cancer, and to pair patients with the most effective possible treatment. From this arm, she reports significant improvement among …
Dr Paul Nghiem speaks with ecancertv at AACR 2016 about his research to treat MCC, a virally induced cancer, using pembrolizumab. The Merkel cell polyoma virus can inhabit human skin, infecting a site in childhood and not become pathogenic until decades later, leading to Dr Nghiem describing the l…
Dr Noriyuki Kasahara speaks with ecancertv at AACR2016 about his cancer-targeting retroviral therapies which illicit host immune responses. Historically, oncolytic viruses have struggled to compete with host immunity to reach their target and the immunosuppresive tumour environment. But by using a…
Disclaimer: The podcast and artwork embedded on this page are from ecancer.org, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.